Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report

Rhea-AI Filing Summary

Aura Biosciences, Inc. filed an initial Form 3 for officer Erica Kratz, who serves as Chief Reg. & Quality Officer. This filing establishes her status as a reporting insider of Aura Biosciences but does not list any reportable transactions or current holdings.

FAQ

What does the Aura Biosciences (AURA) Form 3 for Erica Kratz represent?

The Form 3 for Erica Kratz is an initial insider ownership report. It identifies her as Aura Biosciences’ Chief Reg. & Quality Officer and establishes her as a reporting insider, but it does not disclose any specific transactions or holdings.

Does the Aura Biosciences (AURA) Form 3 show any stock transactions by Erica Kratz?

No. The Form 3 for Erica Kratz reports no transactions. It is purely an initial statement of insider status, with no purchases, sales, or derivative exercises disclosed in this filing.

What role does Erica Kratz hold at Aura Biosciences (AURA) in this Form 3?

In this Form 3, Erica Kratz is identified as an officer of Aura Biosciences with the title Chief Reg. & Quality Officer. This role makes her subject to ongoing insider reporting requirements under SEC rules.

Does the Aura Biosciences (AURA) Form 3 indicate that Erica Kratz is a 10% owner?

No. The Form 3 indicates that Erica Kratz is not a 10% owner. She is classified as an officer only, which still requires insider reporting but does not imply large equity ownership in this filing.

Are any derivative securities reported for Erica Kratz in Aura Biosciences (AURA) Form 3?

No derivative positions are reported for Erica Kratz in this Form 3. The derivative summary section is empty, meaning no options, warrants, or similar instruments are disclosed in this initial statement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/12/2026 - 04:12 PM Accepted by SEC EDGAR 08/12/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kratz Erica

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Reg. & Quality Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Amy Elazzouzi, as Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)